Sana Biotechnology, Inc. $SANA

What the company doesAI summary of filing

Sana Biotechnology develops engineered cell therapies using ex vivo and in vivo cell engineering platforms. The company is currently advancing two main product candidates: SC451, a hypoimmune-modified stem cell-derived pancreatic islet cell therapy for type 1 diabetes (in preclinical and early clinical stages), and SG293, an in vivo CAR T cell therapy for B cell cancers and autoimmune diseases (in preclinical development). The company is pre-revenue and operates at a clinical-stage level, with positive data from an early investigator-sponsored study of UP421, a related primary islet cell therapy, demonstrating survival and function of transplanted cells without immunosuppression for 12 months. [10-K 2026-03-03]

Segments: SC451 (iPSC-derived hypoimmune pancreatic islet cells for type 1 diabetes), SG293 (in vivo CAR T cells for B cell cancers and autoimmune diseases), UP421 (HIP-modified primary islet cell therapy)